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Abstract Assessing hormone receptor status is an essential
part of the breast cancer diagnosis, as this biomarker greatly
predicts response to hormonal treatment strategies. As such,
hormone receptor testing laboratories are strongly encouraged
to participate in external quality control schemes to achieve
optimization of their immunohistochemical assays. Nine
Dutch pathology departments provided tissue blocks con-
taining invasive breast cancers which were all previously
tested for estrogen receptor and/or progesterone receptor
expression during routine practice. From these tissue blocks,
tissue microarrays were constructed and tested for hormone
receptor expression. When a discordant result was found
between the local and TMA result, the original testing slide
was revised and stainingwas repeatedonawhole-tissueblock.
Sensitivity and specificityof individual laboratories for testing
estrogen receptor expression were high, with an overall
sensitivity of 99.7 and 95.4 %, respectively. Overall sensi-
tivity and specificity of progesterone receptor testing were
94.8 and 92.6 %, respectively. Out of 96 discordant cases, 36
caseswouldhavebeen concordant if the recommended cut-off
value of 1 % instead of 10 % was followed. Overall sensi-
tivity and specificity of estrogen and progesterone receptor
testingwere high among participating laboratories. Continued
enrollment of laboratories into quality control schemes is
essential for achieving andmaintaining the highest standardof
care for breast cancer patients.
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Introduction
Testing estrogen receptor (ER) expression is mandatory for
all breast carcinomas as this biomarker predicts response to
estrogen-modulating therapy [1]. Adequate testing of ER
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expression via immunohistochemistry is considered the
gold standard for selecting patients for neoadjuvant and
adjuvant hormonal therapies [2]. The progesterone receptor
(PR) has been assessed as a prognostic factor [3] and as a
potential predictive marker [4, 5]. Initial studies on the
quality of hormone receptor (HR) testing have shown cause
for concern with a low percentage of laboratories showing
acceptable performance [6]. An American Society of
Clinical Oncology (ASCO) and College of American
Pathologists (CAP) panel addressed the need for improving
ER and PR testing and published a set of guidelines con-
cerning this matter [7]. Recommendations were also made
to lower the positivity threshold from 10 to 1 %. Unfor-
tunately, a significant (although decreasing) number of
laboratories still fail to achieve sufficient testing quality in
the NordiQC and/or NEQAS ER and PR assessment runs.
This current study was designed to evaluate a tissue
microarray (TMA)-based method for assessing ER and PR
testing quality. This method allows pathology laboratories
to evaluate the reproducibility of IHC testing results by
retesting a high number of ER and PR assays on TMAs. By
comparing the original result to the retested assay on
TMAs, discordances between local report and retested
tumors can be easily assessed at large scale. Additionally,
the effect of the recommended threshold change of 10–1 %
positive cells on testing reproducibility was investigated.
Methods
Tissues
Formalin-fixed paraffin-embedded (FFPE) tumor blockswere
collected for TMA construction from nine laboratories in the
Netherlands: the Academic Medical Center (AMC, Amster-
dam), Netherlands Cancer Institute/Antoni van Leeuwenhoek
(NKI/AVL, Amsterdam), Diakonessenhuis (Utrecht), Isala
(Zwolle), Leiden University Medical Center (LUMC, Lei-
den), University Medical Center Groningen (UMCG,
Groningen), Eramus Medical Center (EMC, Rotterdam),
Radboud University Medical Center (Radboud UMC Ni-
jmegen), and Laboratory Pathology Eastern Netherlands
(LabPON) (Table S1). The tissue blocks contained invasive
breast carcinomas thatwere previously tested for ER, PR, and/
or HER2 expression by immunohistochemistry as part of
routine pathological diagnostics. HER2 testing quality for a
subset of the included tumors was investigated in a previous
publication [8]. According to Dutch law, these tissue blocks
can be freely used for research purposes after anonymization,
provided that these are handled according to national ethical
guidelines (‘Code for Proper Secondary Use of Human Tis-
sue’, Dutch Federation ofMedical Scientific Societies). TMA
sections were stained with SP1 (for ER) and 1E2 (for PR)
antibodies using the Benchmark XT autostainer (Ventana
Medical Systems, Tucson, AZ, United States).
Comparison of ER and PR test results
The TMA cores were scored by determining the percentage
of nuclear staining and invasive tumor cells (staining inten-
sity was not accounted) in increments of 10 %. ER and PR
results from the original tests were retrieved from the local
pathology reports. These ER and PR scores were compared
to the results that were obtained from the TMA cores. For
discordant cases, whole-tissue sections were sectioned and
stained for ER and PR. This was done to rule out that dis-
cordant results were due to sampling errors introduced by the
use of TMAs. If the results between the local pathology
reports were concordant with the whole slide, the final result
was considered concordant. If the result was still discordant
with the original pathology report, this tumorwas considered
as truly discordant and the reason for the discordancy was
then investigated. For this purpose, the original slides used
for the local ER and PR diagnosis were centrally reviewed. If
the revision of the original testing slide by the central revi-
sion panel revealed discordance with the local observer, the
reason of the discordant result was considered to be observer
inaccuracy. If the original testing slide showed positive
nuclear staining in revision, but this positive IHC result could
not be reproduced on both TMA and subsequent whole-sized
slides despite appropriate positive controls, the reason for the
discordant result was a false-positive IHC procedure. In case
of the opposite result (negative local IHC result with ER-
positive results on TMA and whole-sized slides), the reason
of discordance was considered to be inaccurate IHC leading
to false-negative results. The workflow of the study is sum-
marized in Fig. S1.
Adjustment from 10 to 1 % threshold for HR
positivity
Since all these materials were originally tested prior to the
recommended threshold of 1 % for HR positivity, we then
investigated the influence of the change of this threshold
from 10 to 1 % positive cells as is recommended by the
ASCO/CAP guidelines. For all discordant cases, we
investigated whether this discordancy would still exist after
changing this scoring methodology.
Results
ER concordance
Anumber of 1736 invasive breast carcinomas thatwere tested
for ER in nine different pathology laboratories were included
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in this study. Of these, 163 tumors were omitted from the
analysis when the original ER result could not be retrieved,
when TMA cores were lost during the staining procedure, or
due to the absence of invasivebreast cancer on theTMAcores.
A further four tumorswere excluded becausematerialwas not
available for subsequent retesting after an initial discordant
result was found between the TMA and the original testing
result. The subsequent analysis was performed on the
remaining cohort of 1569 breast tumors (Fig. 1). When
comparing the local testing result with the TMA result, 52
tumorswere considered to bediscordant. For these tumors, the
whole-sized sectionswere stained for ER in order to assess the
reason for discordance. If the whole-slide result was concor-
dant with the original ER testing result, the discordance was
decided to be due to sampling error due to use of a TMA and
the final results were thus concordant (N = 36). If the dis-
cordance remained, this was considered a true discordant
result (N = 16). Of the 16 discordant cases, 12 were false
positive and 4 were false negative (Fig. 1; Table 1). Overall
concordance was 99.0 %, and the sensitivity and specificity
for all ER tests performed by the combined nine centers
showed a sensitivity of 99.7 % (range 98.7–100.0 %) and
specificity of 95.4 % (range 83.3–100.0 %). Positive predic-
tive value (PPV) and negative predictive value (NPV) for all
centers combined were 99.1 % (range 97.4–100.0 %) and
98.4 % (range 90.9–100 %), respectively.
The next step was to investigate whether the discordant
results were due to observer inaccuracy or inaccurate IHC
procedures. To assess the possibility of observer error, the
original slides were revised when available (N = 15). In 12
tumors, discordance between the local observer and the
revision panel was present, which can be considered to be
observer inaccuracy. Three discordant cases were due to
inaccurate IHC procedures. Two showed ER-positive
staining in the local testing center (which was also verified
with slide revision), while no positive test result was
obtained if the staining was repeated (example shown in
Fig. 2). The opposite was true for the third discordant case.
The reason for the discordant result could not be ascer-
tained for the sole remaining tumor, since the unavail-
ability of the original slide leaves it impossible to
determine whether the discordance was due to inaccurate
scoring or IHC procedure (Table 1).
PR concordance
A number of 1518 PR-tested cases were provided by 8
laboratories that performed PR testing. A number of 171
Fig. 1 Concordance for ER
testing results
Table 1 Discordant ER results
N Local ER testing
result
ER result after revision
of original slide
TMA and whole-slide
ER result
Conclusion Reason for
discordance
1 Negative Negative Positive False negative IHC error
3 Negative Positive Positive False negative Observer error
2 Positive Positive Negative False positive IHC error
9 Positive Negative Negative False positive Observer error
1 Positive Unknown Negative False positive Unknown
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cases were excluded from the final analysis. This left a
number of 1347 PR-tested tumors available for the com-
parison with the TMA results (Fig. S2). A total number of
150 tumors were discordant between the original PR test-
ing result and the TMA, and for all these cases, the PR test
was performed centrally on a whole-tissue block. True
discordant results were seen in 80 cases, which led to an
overall concordance of 94.1 %. Of these 80 discordant
cases, 32 tumors were deemed false positive and 48 tumors
were considered false negative (Table S2; Fig. S2). Overall
sensitivity and specificity for PR testing were slightly
lower than for ER testing, with overall sensitivity of
94.8 % and overall specificity of 92.6 %. Sensitivity and
specificity values of individual laboratories ranged from
87.1 to 97.8 % and 85.7–97.0 %, respectively. PPV and
NPV overall were 96.4 % (range 92.6–98.7 %) and 89.3 %
(range 80.0–96.6 %), respectively. With the aid of the
revision of the local PR test (available for 59 of the 80
tumors) and the whole-tissue retesting, the reason for dis-
cordant results was investigated. Observer inaccuracy was
detected in 20 cases, and the IHC test was irreproducible in
39 cases (Table S2).
Consequence of threshold adjustment
All discordant cases were again reviewed to determine
whether adjusting the original or retested ER or PR result,
based on the 2010 ASCO/CAP guidelines, would influence
the discordant result. For some cases, this required the
availability of data regarding the number of HR-positive
cells (if any) observed during the original, local HR testing.
This is important in the case of a tumor that was deter-
mined to be negative at local testing according to the 10 %
cut-off, since such tumors might either be completely
negative or have some positive staining but less than 10 %
overall. For some cases, this information was unavailable
in the pathology report (N = 8). Regardless, out of 96
initially discordant results, applying the recommended 1 %
cut-off leads to a concordant result for 36 tumors (further
described in Table 2).
Discussion
Our study assessed the reproducibility of immunohisto-
chemical ER and PR testing performed in nine testing
laboratories in the Netherlands. For this purpose, TMAs
were used to facilitate retesting relatively high numbers of
previously tested tumors and thus provide an accurate
assessment of the reproducibility of these IHC tests. We
compared the original ER and PR results from the
pathology archives with the result that was detected on
TMA. For discordant results, whole-tissue sections were
tested to rule out the possibility of sampling error. If a
tumor tested negative at a local center, but showed positive
HR expression on both TMA and whole-slide examination,
Fig. 2 Acasewhere the local resultwas determined asER-positive,while
this stainingwas not reproduced on the TMAcore andwhole-slide testing.
A. The local slide which showed both nuclear and smudgy, weaker
cytoplasmic staining in the tumor cells as well as associated fibroblasts. A
nearby duct is strongly positive. B. The TMA test showing no staining in
tumor cells. C.Whole-slide test which verified the ER-negative staining of
the TMA, while the normal duct shows an appropriate positive control
250 Breast Cancer Res Treat (2015) 152:247–252
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this tumor is likely to indeed have HR expression. If a
tumor shows positive HR expression at the local center, but
both TMA and whole-sized stainings are unable to repli-
cate this staining (despite appropriate internal and external
controls), it is hard to say whether the first positive result
was truly false positive. Careful examination of the slide
with knowledge of expected staining patterns might how-
ever be helpful (Fig. 2). Unfortunately, no gold standard
exists that could have been used to determine which
assessment is correct which remains a weakness of this
study design. Response to hormonal therapy should be the
gold standard in these cases, but this is also dependent on
other known and unknown variables, and information
regarding hormonal response is not always available. Viale
et al. showed that a group of tumors that were locally ER-
positive while centrally ER-negative tended to follow the
overall survival patterns of ER-negative tumors (namely
early relapse with following plateau, whereas ER-positive
tumors follow a slower rate of relapse) [9]. These obser-
vations speak in favor of centrally performed HR tests in
general, but this cannot be applied to each individual. Other
studies have used RT-PCR as an additional method for
determining HR status in addition to local and central IHC,
but these assays are neither free from reproducibility issues
themselves nor have been shown to correlate more closely
to response to hormonal therapy [10].
Fortunately, concordance between local and retested HR
results was high for both ER (99.0 %) and PR (94.1 %) in
this current study. Remarkably, irreproducible test results
obtained for ER were only rarely due to errors in the IHC
procedure, whereas the ratio of IHC procedure error to
observer error was more balanced in the PR-tested group.
This might be due to the quality of the antibodies, as tra-
ditionally more emphasis has been placed on ER testing
quality.
A 2010 report by an ASCO/CAP panel has suggested
lowering the threshold of positivity from 10 % HR-positive
cells to 1 %. These guidelines were established along a
similar methodology as an earlier report concerning HER2
testing which recommended increasing the positivity
threshold to 30 % positive cells [11]. The ER/PR guideline
adjustments were not designed to improve testing accuracy,
but were based on the observation that even patients with
low percentage HR cells (1–10 %) still respond to
tamoxifen. This is despite the observation that most tumors
with 1–10 % HR? cells share more common biologic
features with ER- tumors [12]. Regardless, this change
might also have consequences for HR testing repro-
ducibility in this rare [13] group of tumors, which was
investigated in this study. We found that a substantial
number of these cases that were discordant between local
and TMA testing were concordant when following the
2010 ASCO/CAP guidelines, suggesting that adherence to
the 2010 guidelines improves the reproducibility of HR
testing results.
Central assessment of ER and PR status of tumors that
were included into the Breast International Group (BIG)
1–98 trial showed that locally tested ER-negative tumors
tend to show ER positivity in a relatively high number of
cases (69.5 %) [9]. Discordance was even more pro-
nounced for PR testing [9]. Retesting of HR-tested tumors,
included in the Eastern Cooperative Oncology Group
(ECOG) study E2197, showed a concordance of 90 and
84 %, respectively, between locally tested and centrally
tested ER and PR results [10]. Central review of local HR
testing performed in the Adjuvant Lapatinib and/or Tras-
tuzumab Treatment Optimisation (ALTTO) showed that
local ER-positives could not be reproduced for 4.3 % of
cases. Even more worrisome was the poor reproducibility
of 21.6 % of ER-negative results which displayed positive
staining when retesting of the original result was performed
[14]. All of these studies indicate (i) a relatively poor
reproducibility of ER-negative test results, (ii) an average
reproducibility of ER testing below 95 %, and (iii) an even
lower reproducibility for PR testing. A 2014 report by
Viale et al. published the concordance from the ER and PR
testing performed locally for the first 800 participants of
the MINDACT trial with central IHC retesting [15]. Con-
cordance for ER and PR IHC tests was determined as 97.6
and 89.6 %, respectively. These last results and ours
Table 2 Discordant results reevaluated according to 2011 ASCO/CAP guidelines
N Percentage of HR-
positive cells in
local result
Threshold
at 1 %
Threshold at 10 %
(reported in
pathology report)
Percentage of HR-
positive cells at
retesting
Threshold
at 1 %
Threshold
at 10 %
Discordant at
10 %
threshold?
Discordant
at 1 %
threshold?
12 \10 % but C 1 % Positive Negative C10 % Positive Positive Yes No
24 C10 % Positive Positive \10 % but C 1 % Positive Negative Yes No
8 Not reported Unknown Negative C10 % Positive Positive Yes Unknown
29 C10 % Positive Positive 0 % Negative Negative Yes Yes
23 0 % Negative Negative C10 % Positive Positive Yes Yes
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indicate an improving trend in ER and PR testing repro-
ducibility. The relatively high reproducibility in our study
might be explained by the routine use of autostainers
among all participating laboratories. Also, the participating
centers in this study were all accredited laboratories in the
Netherlands, leaving the question whether these results
apply to all individual centers.
Continuous improvement of local IHC methods and
validation of these are of essential importance to provide
and maintain optimal care for breast cancer patients. Par-
ticipation in such quality control schemes should be con-
sidered as mandatory for every individual HR testing
laboratory. The tissue microarray approach described in
this study can provide important feedback regarding testing
reproducibility.
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